Biotechnology

RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions

August 19, 2026 7:25 PM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the connection details for its first-ever investor call, during which management will present prepared remarks responding to questions submitted by shareholders. The call reflects the Company's strong performance through the first half of 2026...

Read more

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

August 19, 2026 3:45 PM

OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule...

Read more

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

August 19, 2026 6:30 AM

OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. To Every OSR Health Shareholder, Wherever You Are: OSR Health is at an inflection point, one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market. Before that recognition fully arrives, I want to speak directly to the shareholders who have been here all...

Read more

Biovica Receives New Extensive Pharma Services Work Order from Existing Customer

August 19, 2026 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring and oncology drug development services, today announced that it has received a new Pharma Services work order from an existing TIER-2 pharmaceutical customer. The work order covers DiviTum® TKa testing for an early-stage clinical development program in breast cancer evaluating a novel therapy within the CDK2/4 inhibitor...

Read more

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

August 19, 2026 2:25 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report its unaudited half-year financial results for the six months ended 30 June 2026, on Wednesday, 26 August 2026. A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer and Jurriaan Dekkers, Chief Financial...

Read more

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets

August 18, 2026 4:30 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced significant improvements to its manufacturing process for N-trans-caffeoyltyramine ("NCT"), marking a significant step toward scalable commercial production. Building on learnings from the Company's previously announced 100-liter pilot run, the optimized process...

Read more

Imagene AI Joins Proscia Ready Partner Alliance to Advance AI-Powered IHC Companion Diagnostics Development

August 18, 2026 8:00 AM

Imagene AI, a leader in AI-powered precision oncology, today announced that it has joined the Proscia Ready partner alliance. Imagene AI is collaborating with Proscia® to integrate its advanced H&E tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia's Concentriq® platform. The integration will support the use of H&E-based patient screening tools to inform molecular testing, as well as AI-powered image analysis for the...

Read more

Lobe Sciences Reports Third Quarter 2026 Financial Results

August 18, 2026 8:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its unaudited interim financial results for the third quarter of fiscal 2026 ended May 31, 2026 ("Q3 2026"). During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined...

Read more

RMTG Expands Cellgenic's Cancún Laboratory Infrastructure with Two Additional ISO 7 Clean Rooms

August 18, 2026 7:00 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced an expansion of its Cellgenic division's flagship laboratory facilities in Cancún, Mexico, adding two ISO 7-classified clean rooms to the Company's existing laboratory infrastructure. The additional capacity is intended to support increased...

Read more

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

August 17, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. During the second quarter, the Phase 2 CALMA trial of IGC-AD1 reached the Company's previously disclosed 146-patient baseline randomization...

Read more

NatureCell to Open the Era of "Medicine for Humanity (蒼生醫學)" with the World's First Commercialization of Amniotic Stem Cell Conditioned Medium

August 17, 2026 8:00 AM

NatureCell announced its vision to usher in an era of "Medicine for Humanity (蒼生醫學)" by commercializing amniotic stem cell conditioned medium (CM) for the first time in the world and making advanced stem cell technologies more economical and convenient for people around the world. The latest research supporting this vision was published in the international scientific journal Cells on August 13, 2026. The study investigated the use of amniotic...

Read more

Research Labs Reviews and Complaints 2026: Looking for a More Transparent Research Peptide Supplier? Explore the Batch COAs

August 14, 2026 11:00 PM

This is a paid advertorial. A commission is earned if you purchase through links in this article. Product claims are attributed to the brand and are not independently endorsed. Research Labs sells research peptides labeled for research use only - not for human or animal consumption - and the FDA has not evaluated the statements made about these products. Official site: researchlabs.com. This is informational content for qualified research...

Read more

CARR Biosystems Acquires Alfa Wassermann, Expanding Its Bioprocessing Portfolio

August 14, 2026 9:00 AM

CARR Biosystems, a provider of separation and bioprocessing technologies for the pharmaceutical and biotechnology industries, today announced it has acquired Alfa Wassermann (AW), a leader in continuous flow ultracentrifugation and fluid handling solutions, from Turytes S.p.A.. The transaction closed on August 10th. For more than 60 years, AW has designed, manufactured and serviced continuous flow ultracentrifugation systems used to separate,...

Read more

Notice Of Annual General Meeting in Biovica International AB

August 14, 2026 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the annual general meeting to be held on Wednesday 16 September 2026, at 15.00 CEST at Conference Hubben, Dag Hammarskjölds Väg 38 in Uppsala. Right to attend the general meeting Shareholders wishing to attend the annual general meeting must: i. on the record date, which is on...

Read more

Lifeloc Reports Second Quarter 2026 Results

August 13, 2026 4:18 PM

Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2026. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.445 million in the second quarter of 2026, resulting in a quarterly net loss of $(134) thousand, or $(0.05) per diluted share. These results compare to net revenue...

Read more

First Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory Board

August 13, 2026 2:25 PM

First Ascent Biomedical, a precision oncology company developing biology-driven cancer treatment decision support, today announced the appointment of Gilberto Lopes, M.D., as Chairman of the company's Medical Advisory Board. Dr. Lopes is Professor of Clinical Medicine and Chief of the Division of Medical Oncology at the University of Miami Miller School of Medicine. He also serves as Associate Director for Global Oncology at Sylvester...

Read more

AlivaMab Biologics and Ablexis Congratulate Boulevard Bio on its Launch and the Ongoing Phase 1 Clinical Trial of Bispecific Antibody BLVD101

August 13, 2026 9:30 AM

AlivaMab Biologics, LLC ("AMB"), a leader in the discovery and engineering of superior biologic drugs, and Ablexis, LLC ("Ablexis"), a biopharmaceutical company advancing human antibody drug discovery through the provision of its AlivaMab® Mouse technology, congratulate Boulevard Bio on its launch and the ongoing Phase 1 clinical trial for BLVD101, a dual neutralizing bispecific antibody for the treatment of autoimmune diseases. "Working in...

Read more

Microbix Reports Results for Q3 Fiscal 2026

August 13, 2026 7:50 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 17% in Q3 compared to Q3...

Read more

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

August 12, 2026 8:45 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce a non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private...

Read more

Levita Magnetics Brings MARS(R) Magnetic Surgery Platform to Florida for the First Time

August 12, 2026 6:00 AM

Levita Magnetics, a Silicon Valley medical technology company advancing minimally invasive surgery, has performed its first Magnetic Surgery procedures in Florida using the MARS® platform. The milestone marks the Florida debut of MARS® at HCA Florida Mercy Hospital in Miami, the first hospital in the state to offer this technology, expanding access to less invasive surgery in Florida. Built on Levita's proprietary Dynamic Magnetic Positioning™...

Read more